GLENMARK FILES PHASE I APPLICATION FOR ITS ANTI-DIABETIC IN UK
Glenmark Pharmaceuticals SA filed for Phase I clinical trials for its leading DPP-IV inhibitor compound, GRC 8200 with Medicines and Healthcare Products Regulatory Agency (MHRA) in UK. A leading global CRO Parexel UK will conduct the Phase I study. Phase I study is expected to be completed in February 2006 and will be conducted using single and multiple oral doses on healthy volunteers. The objective of this study is to assess the safety and bio-availability of GRC 8200 in humans.
Express Pharma Pulse (http://www.expresspharmapulse.com/20051006/marketplace01.shtml)